After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease1 Data also show a 29.1% risk reduction in distant disease-free survival, and a positive trend in overall survival*1 With a median of around t ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy aloneIn the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefitResults reinforce two years of Verzenio plus endocrine therapy as the standard of care in HR+, HER2-, node-positive, early breast cancer at a high risk of recu ...